###begin article-title 0
###xml 14 19 14 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 33 38 <span type="species:ncbi:9606">human</span>
Regulation of MYCN expression in human neuroblastoma cells
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 21 26 21 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 99 103 99 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN</italic>
###xml 172 177 172 177 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 243 248 243 248 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 365 371 365 371 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCNOS</italic>
###xml 404 413 404 409 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#916;MYCN</italic>
###xml 467 474 463 470 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCNOS </italic>
###xml 180 188 <span type="species:ncbi:9606">children</span>
###xml 287 295 <span type="species:ncbi:9606">children</span>
Amplification of the MYCN gene in neuroblastoma (NB) is associated with a poor prognosis. However, MYCN-amplification does not automatically result in higher expression of MYCN in children with NB. We hypothesized that the discrepancy between MYCN gene expression and prognosis in these children might be explained by the expression of either MYCN-opposite strand (MYCNOS) or the shortened MYCN-isoform (DeltaMYCN) that was recently identified in fetal tissues. Both MYCNOS and DeltaMYCN are potential inhibitors of MYCN either at the mRNA or at the protein level.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 14 27 14 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN, MYCNOS </italic>
###xml 31 41 31 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#916;MYCN </italic>
###xml 299 304 295 300 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 57 62 <span type="species:ncbi:9606">human</span>
Expression of MYCN, MYCNOS and DeltaMYCN was measured in human NB tissues of different stages. Transcript levels were quantified using a real-time reverse transcriptase polymerase chain reaction assay (QPCR). In addition, relative expression of these three transcripts was compared to the number of MYCN copies, which was determined by genomic real-time PCR (gQPCR).
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 5 15 5 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#916;MYCN </italic>
###xml 19 26 15 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCNOS </italic>
###xml 73 77 69 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN</italic>
###xml 160 175 156 167 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN:&#916;MYCN </italic>
###xml 239 249 231 237 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#916;MYCN </italic>
###xml 253 258 241 246 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 362 374 346 358 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCNOS:MYCN </italic>
###xml 431 433 415 417 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 487 491 471 475 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN</italic>
###xml 523 530 507 514 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCNOS </italic>
###xml 556 560 540 544 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN</italic>
###xml 595 602 579 586 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCNOS </italic>
###xml 681 686 665 670 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
Both DeltaMYCN and MYCNOS are expressed in all NBs examined. In NBs with MYCN-amplification, these transcripts are significantly higher expressed. The ratio of MYCN:DeltaMYCN expression was identical in all tested NBs. This indicates that DeltaMYCN and MYCN are co-regulated, which suggests that DeltaMYCN is not a regulator of MYCN in NB. However, the ratio of MYCNOS:MYCN expression is directly correlated with NB disease stage (p = 0.007). In the more advanced NB stages and NBs with MYCN-amplification, relatively more MYCNOS is present as compared to MYCN. Expression of the antisense gene MYCNOS might be relevant to the progression of NB, potentially by directly inhibiting MYCN transcription by transcriptional interference at the DNA level.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 4 15 4 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCNOS:MYCN</italic>
###xml 67 71 67 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN</italic>
###xml 176 183 176 183 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCNOS </italic>
The MYCNOS:MYCN-ratio in NBs is significantly correlated with both MYCN-amplification and NB-stage. Our data indicate that in NB, MYCN expression levels might be influenced by MYCNOS but not by DeltaMYCN.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 50 55 50 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 94 99 94 99 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN-</italic>
###xml 167 172 167 172 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 193 194 193 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 195 196 195 196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 260 265 260 265 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 357 361 357 361 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN</italic>
###xml 494 499 494 499 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 507 512 507 512 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DDX1 </italic>
###xml 533 537 533 537 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAG </italic>
###xml 564 571 564 571 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCNOS </italic>
###xml 585 586 585 586 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 587 588 587 588 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 797 801 797 801 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN</italic>
###xml 852 857 852 857 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DDX1 </italic>
###xml 861 865 861 865 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAG </italic>
###xml 933 934 933 934 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 175 183 <span type="species:ncbi:9606">children</span>
###xml 923 931 <span type="species:ncbi:9606">patients</span>
Neuroblastoma cells (NBs) that carry an amplified MYCN gene are extremely malignant. However, MYCN-amplification does not automatically result in higher expression of MYCN in children with NB [1-3]. Thus, it has been suggested that the aggressive phenotype of MYCN amplified NBs may be explained by higher expression levels of other genes co-amplified with MYCN, since the amplified unit of DNA can be up to 1 Mb. To date, three genes have been identified that are frequently co-amplified with MYCN in NBs: DDX1 in 50% of the cases, NAG in 20% of the tumours, and MYCNOS in all cases [4,5]. All three genes demonstrate increased transcript expression when co-amplified in NB cell lines, indicating that they may contribute to tumour phenotype. However, survival analyses in a large study using 75 MYCN-amplified tumours indicate that neither amplified DDX1 nor NAG have an additional adverse effect on the prognosis of the patients [6].
###end p 11
###begin p 12
###xml 66 67 66 67 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 68 69 68 69 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 155 157 155 157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 341 343 341 343 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 344 346 344 346 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 349 356 349 356 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCNOS </italic>
###xml 387 392 387 392 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 393 395 393 395 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 438 442 438 442 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN</italic>
###xml 520 525 520 525 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 666 668 666 668 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 669 671 669 671 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 704 715 704 711 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HIF-1&#945; </italic>
###xml 787 789 783 785 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 75 80 <span type="species:ncbi:9606">human</span>
###xml 766 771 <span type="species:ncbi:9606">human</span>
Natural antisense transcripts are abundant in eukaryotic genomes [7-9]. In human, more than 1600 natural antisense transcript are predicted to be present [10]. They can influence gene expression on the DNA level by transcriptional interference, on the transcript level by RNA interference and RNA editing, or direct splicing by RNA masking [11,12]. MYCNOS is the antisense transcript of MYCN [13] and shows overlap with the first exon of MYCN. This antisense transcript could be involved in modulating the expression of MYCN by any of the mechanisms mentioned above. Antisense transcripts are considered to be relevant to the development and progression of tumours [14-16], but until now, only antisense HIF-1alpha RNA has been shown to be a marker for prognosis in human breast cancer [17].
###end p 12
###begin p 13
###xml 51 60 51 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#916;MYCN</italic>
###xml 78 80 74 76 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 87 97 83 89 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#916;MYCN </italic>
Recently, we reported a fetal MYCN splice variant (DeltaMYCN) lacking exon 2 [18]. The DeltaMYCN transcript is expressed in several fetal tissues and contains the acidic region, nuclear localization signal, the basic helix-loop-helix and leucine-zipper domains but lacks the transactivation domain. It has been suggested that the DeltaMYCN protein may serve as an obligate dimerization partner for MYCN to convey transcriptional activation or repression.
###end p 13
###begin p 14
###xml 49 59 49 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#916;MYCN </italic>
###xml 63 70 59 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCNOS </italic>
###xml 80 85 76 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
In this report we analysed whether expression of DeltaMYCN and MYCNOS influence MYCN expression levels in NBs of different disease stages.
###end p 14
###begin title 15
Methods
###end title 15
###begin title 16
Tumour material
###end title 16
###begin p 17
###xml 528 532 526 530 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN</italic>
###xml 162 170 <span type="species:ncbi:9606">patients</span>
Sixteen fresh-frozen NBs were obtained from at the Department of Pathology at the Radboud University Nijmegen Medical Centre. All NBs were derived from pediatric patients (0 to 6-years-old) diagnosed at the Department of Pediatric Hemato-Oncology. Sections of the frozen samples were stained with hematoxylin-eosin and reviewed by the pathologist to verify tumour histology and to evaluate the percentage of tumour cells. Samples were only considered for study if the contents of tumour cells was >/= 75%. Six out of 16 NBs had MYCN-amplification as shown by southern blot and/or fluorescent in situ hybridization (FISH). All samples were anonymized prior to this study, and the research program was approved by the local ethics committee (Commissie Mensgebonden Onderzoek Regio Arnhem-Nijmegen).
###end p 17
###begin title 18
DNA isolation, RNA isolation and cDNA synthesis
###end title 18
###begin p 19
Tumour samples were aliquoted in two parts to isolate both DNA and RNA. Total DNA was isolated with the QIAamp isolation-kit (Qiagen, Hilden, Germany) according to the manufacturer's protocol. All samples were RNAse treated. Total RNA was isolated with TriZol reagent (Invitrogen, Carlsbad, CA, USA) and treated with Deoxyribonuclease I (Dnase I; Invitrogen). DNase-treated RNA was reverse-transcribed using oligo(dT) primers with the SuperScript First-Strand Synthesis System (Invitrogen).
###end p 19
###begin title 20
PCR
###end title 20
###begin p 21
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 180 182 180 182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 222 223 222 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 259 264 259 264 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 287 288 287 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
MYCN and splice variants were amplified from cDNA by using the GC-RICH PCR System (Roche Applied Science, Almere, The Netherlands). Primers were developed by the primer3 program ([19]). Primer sequences are shown in table 1 and the position of the primers in MYCN are depicted in figure 1. PCR products were sequenced using the ABI PRISM BigDye Terminator Cycle Sequencing V2.0 Ready Reaction Kit and analysed with the ABI PRISM 3730 DNA analyser (Applied Biosystems, Foster City, CA, USA).
###end p 21
###begin p 22
###xml 93 98 93 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 102 108 102 108 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCNOS</italic>
###xml 0 108 0 108 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Schematic overview of (A) genomic organization, (B) transcripts, and (C) protein isoforms of <italic>MYCN </italic>and <italic>MYCNOS</italic></bold>
###xml 318 322 318 322 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN</italic>
###xml 336 345 336 341 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#916;MYCN</italic>
###xml 257 264 <span type="species:ncbi:9606">patient</span>
Schematic overview of (A) genomic organization, (B) transcripts, and (C) protein isoforms of MYCN and MYCNOS. The localization of primer sites (small arrows) and the C-19 antibody epitope are indicated. (D) RT-PCR with primers on exon 1 and 3 on NB cDNA of patient 13 and NB cell line IMR-32 give products of 1007 bp (MYCN) and 100 bp (DeltaMYCN). The identity of both products was verified by sequence analysis.
###end p 22
###begin p 23
Primer-sequences of primers used in this report.
###end p 23
###begin title 24
QPCR and gQPCR
###end title 24
###begin p 25
###xml 324 325 324 325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 380 381 380 381 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 520 522 520 522 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 523 525 523 525 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 668 681 668 673 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#916;&#916;Ct </sup>
###xml 689 691 681 683 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 692 694 684 686 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 814 816 806 808 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
QPCR and gQPCR was performed by SYBR Green-based quantification (Bio-Rad, Veenendaal, The Netherlands). PCRs were performed on an iCycler (MyiQ single color Real-Time detection System, Bio-Rad, Veenendaal, The Netherlands). Sequences of the primers used to quantify cDNA transcript levels and genomic DNA are shown in table 1 and the position of the primers is depicted in figure 1. PCR products were between 80- and 100-bp. Validation of the primer pairs and (g)QPCR experiments were performed as described previously [20,21]. Differences in expression of a gene of interest or in genomic DNA copy number between two samples were calculated by the comparative Ct or 2DeltaDeltaCt method [22,23]. Hoebeeck et al. described and validated a similar assay for the determination of MYCN copy numbers in tumor samples [24].
###end p 25
###begin title 26
Antibody coupling and immunoprecipitation
###end title 26
###begin p 27
NB-samples were homogenized in RIPA-buffer (50 mM Tris-HCl pH 7.4, 0.2% sodium dodecyl sulfate (SDS), 0.2% sodium deoxycholate, 1% triton X-100, 1 mM EDTA) supplemented with 1 mM DTT, 1 mM PMSF, aprotinin 2 mug/ml and leupeptin 2 mug/ml. Total protein concentration was determined according to the Bradford method (Bio-Rad Laboratories, Hercules, CA, USA).
###end p 27
###begin p 28
For immunoprecipitation, 5 mug C-19 mAb (Santa Cruz Biotechnology, Heidelberg, Germany) was coupled to Prot A sepharose CL-4B beads (Pharmacia Biotechnologies, Uppsala, Sweden) for 1 hour at 4degreesC to). NB-lysates were precleared O/N with 50 mul packed Prot A sepharose CL-4B beads. To the precleared lysates, 20 mul C-19-coupled beads was added and incubated for 24 h at 4degreesC. Subsequently, the beads were washed with PBS and resuspended in SDS sample buffer and stored at -80degreesC until SDS-polyacrylamide gel electrophoresis (PAGE).
###end p 28
###begin title 29
SDS-PAGE and Western blotting
###end title 29
###begin p 30
###xml 309 310 307 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
###xml 656 661 <span type="species:ncbi:9823">swine</span>
###xml 667 673 <span type="species:ncbi:9986">rabbit</span>
Samples (30 mug homogenized NB-sample or 20 mul precipitation beads) were separated a 10% polyacrylamide gels and transferred to nitrocellulose (Hi-bond, Amersham Biosciences, Little Chalfont, UK). Ponceau S staining was used to confirm that equal amounts of protein were loaded in each lane (additional file 1). The nitrocellulose blot was blocked with 1% BSA in 20 mM Tris-HCl pH 7.4 and 0.1% Tween (Tris-buffered saline/Tween 20; TBS-T) for 1 h. The blot was washed for 5 min with TBS-T followed by incubation with the C-19 anti-MYCN antibody 1:200 diluted in TBS-T for 1 h at RT. After washing 3x with TBS-T, the blot was incubated with HRP-conjugated swine-anti-rabbit antibody (1:5000 diluted in TBS-T) for 1 h at RT. Subsequently, the blot was washed and incubated for 1 min with ECL substrate (Amersham Biosciences, Little Chalfont, UK) and exposed to film (Kodak, Rochester, NY, USA).
###end p 30
###begin title 31
Overexpression of MYCNOS in the NB cell line IMR-32
###end title 31
###begin p 32
###xml 33 40 33 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCNOS </italic>
###xml 91 92 91 92 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 95 102 95 102 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCNOS </italic>
###xml 235 242 235 242 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCNOS </italic>
###xml 341 348 341 348 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCNOS </italic>
###xml 520 522 520 522 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 566 573 565 572 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCNOS </italic>
###xml 580 584 579 583 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GFP </italic>
Primers for the amplification of MYCNOS were developed by using the primer3 program (Table 1). MYCNOS was amplified from DNA isolated from a healthy control using the GC RICH PCR System (Roche, Woerden, The Netherlands). Subsequently, MYCNOS was cloned into the Gateway donor vector pDONR-201 (Invitrogen). Using the Gateway cloning system, MYCNOS was subsequently subcloned into the pcDNA3 expression vector and integrity of the construct was validated by sequence analysis. IMR-32 NB cells at 50% confluence in a 25 cm2 flask were co-transfected with 8 mug pcDNA3-MYCNOS and C1-GFP using 120 mul lipofectamine (Invitrogen) in 3 ml Opti-MEM-I for 20 min at RT.
###end p 32
###begin title 33
Statistical analysis
###end title 33
###begin p 34
###xml 55 59 55 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN</italic>
###xml 100 104 100 104 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN</italic>
###xml 173 177 173 177 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN</italic>
###xml 314 318 314 318 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN</italic>
Statistically significant differences in expression of MYCN-transcripts between NBs with or without MYCN-amplification were calculated with Students' T-test. Correlation of MYCN-transcipt expression with disease stage was calculated using the Spearman rank correlation and correlation of MYCN-transcripts with the MYCN-amplification numbers was calculated with the Pearson correlation test. All statistical tests were two-sided, significance was determined as p < 0.05.
###end p 34
###begin title 35
Results
###end title 35
###begin title 36
###xml 0 7 <span type="species:ncbi:9606">Patient</span>
Patient characteristics
###end title 36
###begin p 37
###xml 178 180 178 180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 249 250 249 250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 281 285 281 285 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN</italic>
###xml 47 55 <span type="species:ncbi:9606">patients</span>
###xml 124 132 <span type="species:ncbi:9606">Children</span>
We analysed fresh-frozen NBs from 16 pediatric patients (age range: 0-6 years old). The NBs are classified according to the Children's Cancer Group Neuroblastoma Staging System [25] and treated according to Pediatric Oncology Group-protocols (Table 2). Six out of 16 NBs carried a MYCN-amplification initially detected by Southern blot and/or FISH.
###end p 37
###begin p 38
###xml 0 7 <span type="species:ncbi:9606">Patient</span>
Patient characteristics.
###end p 38
###begin p 39
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
aAge at diagnosis
###end p 39
###begin p 40
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
bNeuroblastoma differentiation as assessed by pathologist. D = differentiated; PD = poorly differentiated; UD = undifferentiated
###end p 40
###begin p 41
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c</sup>
###xml 1 6 1 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
cMYCN genomic amplification, as determined with qPCR
###end p 41
###begin p 42
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">d</sup>
dPatient has been treated before surgery
###end p 42
###begin p 43
BM = bone marrow; d.o.d. = death of disease; MIBG = meta-iodobenzylguanidine; SCR = stem cell rescue; RT = radiotherapy.
###end p 43
###begin title 44
DeltaMYCN expression in the neuroblastoma cell line IMR-32
###end title 44
###begin p 45
###xml 63 67 63 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN</italic>
###xml 139 149 139 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#916;MYCN </italic>
###xml 179 189 175 181 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#916;MYCN </italic>
###xml 317 319 309 311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A</xref>
###xml 330 331 322 323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 550 555 542 547 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 559 569 551 557 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#916;MYCN </italic>
###xml 609 611 597 599 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1D</xref>
###xml 692 697 680 685 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 701 710 689 694 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#916;MYCN</italic>
###xml 1211 1213 1183 1185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 1223 1225 1195 1197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2A</xref>
###xml 1310 1314 1282 1286 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN</italic>
Two splice variants have been described for the proto-oncogene MYCN, the classical transcript that consists of three exons and a shortened DeltaMYCN transcript that lacks exon 2. DeltaMYCN is expressed in several fetal tissues, but its expression has not been reported in NBs. We used primers spanning exon 2 (Figure 1A and Table 1) to visualize by reverse transcriptase PCR whether or not both transcripts are present in MYCN-amplified IMR-32 neuroblastoma cells. Two fragments were identified that corresponded with the expected product lengths of MYCN and DeltaMYCN of respectively 1007 and 100 bp (Figure 1D). Sequence analyses on the excised products confirmed that these fragments were MYCN and DeltaMYCN. Absence of additional fragments in the IMR-32 NB cell line suggests that there are no other major MYCN splice variants. To determine whether the DeltaMYCN protein is expressed in IMR-32 NB cells, MYCN proteins were visualized with the C-19 antibody that recognizes the c-terminal epitope of both MYCN and DeltaMYCN proteins. In the lysate of IMR-32 cells, two protein bands were recognized at approximately 65 and 45 kD, which are the predicted molecular weights of MYCN and DeltaMYCN respectively [18] (Figure 2A). For comparison, in a lysate of the melanoma cell line (BLM), which does not carry MYCN-amplification, no reactivity could be observed. We conclude from these experiments that the fetal MYCN isoform DeltaMYCN is co-expressed with MYCN in IMR-32 cells.
###end p 45
###begin p 46
###xml 0 47 0 43 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Detection of MYCN and &#916;MYCN in IMR-32 cells</bold>
###xml 125 129 121 125 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN</italic>
###xml 281 285 273 277 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN</italic>
Detection of MYCN and DeltaMYCN in IMR-32 cells. (A) Western blot, visualizing two proteins in the IMR-32 (NB cell line with MYCN-amplification) lysate with the C-19 antibody that recognizes the C-terminal epitope of both MYCN and DeltaMYCN. In the BLM (melanoma cell line without MYCN-amplification) lysate, these proteins were not present. (B) Western blot of IMR-32 whole lysate (1), whole lysate minus precipitate (2) and the precipitate (3) using the C-19 antibody. Arrows indicate the positions of MYCN (65 kDa) and DeltaMYCN (45 kDa). The additional band in lane 3 is caused by deposition of Ig-heavy chains (50 kDa). Exposure times are indicated below the blots.
###end p 46
###begin title 47
Quantitative analyses of MYCN, DeltaMYCN and MYCNOS expression levels in neuroblastomas
###end title 47
###begin p 48
###xml 26 30 26 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN</italic>
###xml 32 42 32 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#916;MYCN </italic>
###xml 46 53 42 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCNOS </italic>
###xml 108 109 104 105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 154 165 150 161 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GUSB, TFRC </italic>
###xml 169 176 165 172 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RNFIII </italic>
###xml 177 179 173 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 187 192 183 188 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 196 203 192 199 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCNOS </italic>
###xml 258 268 254 260 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#916;MYCN </italic>
###xml 375 380 367 372 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 392 396 384 388 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN</italic>
###xml 496 500 488 492 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN</italic>
###xml 553 555 545 547 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 585 589 577 581 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN</italic>
###xml 630 640 622 628 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#916;MYCN </italic>
###xml 644 651 632 639 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCNOS </italic>
###xml 696 700 684 688 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN</italic>
###xml 733 735 721 723 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3A</xref>
###xml 73 78 <span type="species:ncbi:9606">human</span>
###xml 322 329 <span type="species:ncbi:9606">patient</span>
mRNA expression levels of MYCN, DeltaMYCN and MYCNOS were measured in 16 human neuroblastoma samples (Table 2) by QPCR relative to three reference genes: GUSB, TFRC and RNFIII [21]. Both MYCN and MYCNOS were found to be expressed in all 16 NBs. In addition, DeltaMYCN expression was detected in all NB samples, except for patient 9, who did not carry an amplification of the MYCN region. For MYCN, it has been demonstrated that the relative expression-levels are significantly higher in NBs with MYCN-amplification as compared to non-amplified tumours [26]. Here, we show that besides MYCN, the relative mRNA expression levels of DeltaMYCN and MYCNOS are also significantly increased in NBs with MYCN-amplification (p < 0.01; Figure 3A).
###end p 48
###begin p 49
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN</italic>
###xml 6 15 6 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#916;MYCN</italic>
###xml 21 28 17 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCNOS </italic>
###xml 0 57 0 53 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>MYCN</italic>, <italic>&#916;MYCN</italic>, and <italic>MYCNOS </italic>mRNA expression levels in NBs</bold>
###xml 84 100 80 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN, &#916;MYCN </italic>
###xml 104 111 96 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCNOS </italic>
###xml 114 118 106 110 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN</italic>
###xml 234 239 226 231 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 259 269 251 257 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#916;MYCN </italic>
###xml 290 297 278 285 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCNOS </italic>
###xml 326 331 314 319 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN-</italic>
###xml 375 386 363 374 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN:MYCNOS</italic>
###xml 410 414 398 402 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN</italic>
###xml 462 466 450 454 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN</italic>
###xml 530 535 518 523 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 547 559 535 547 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN:MYCNOS </italic>
###xml 622 632 610 620 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN:MYCN </italic>
###xml 715 726 703 714 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN:MYCNOS</italic>
###xml 771 786 759 770 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN: &#916;MYCN</italic>
###xml 909 911 893 895 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
MYCN, DeltaMYCN, and MYCNOS mRNA expression levels in NBs. (A) Expression levels of MYCN, DeltaMYCN and MYCNOS in MYCN-amplified (closed-triangles) compared to non-amplified (open triangles) tumours. (B) Relative expression-levels of MYCN (closed triangles), DeltaMYCN (closed circles) and MYCNOS (open circles) correlated to MYCN-amplification in NBs. (C) Difference of the MYCN:MYCNOS-ratio between NBs with MYCN-amplification (closed circles) and NBs without MYCN-amplification (open circles). (D) Correlation of the number of MYCN copies with MYCN:MYCNOS mRNA ratios (closed circles and non-interrupted line) and with MYCN:MYCN mRNA ratios (open triangles and dotted line). (E) Correlation between NB stage and MYCN:MYCNOS-ratio. (F) Correlation between NB stage and MYCN: DeltaMYCN-ratio. NB IV-s is a special type of NB characterized by metastatic disease with spontaneous regression and good survival [31].
###end p 49
###begin p 50
###xml 29 43 29 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN:&#916;MYCN</italic>
###xml 66 80 62 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN:&#916;MYCN</italic>
###xml 136 140 128 132 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN</italic>
###xml 163 165 155 157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3C</xref>
###xml 178 179 170 171 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 252 254 244 246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3F</xref>
###xml 267 268 259 260 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 387 398 379 390 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN:MYCNOS</italic>
###xml 414 418 406 410 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN</italic>
###xml 441 443 433 435 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3C</xref>
###xml 456 457 448 449 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 494 496 486 488 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3E</xref>
###xml 509 510 501 502 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 531 547 523 535 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCNOS:&#916;MYCN</italic>
###xml 595 599 583 587 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN</italic>
###xml 638 639 626 627 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 764 769 752 757 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCNO</italic>
###xml 793 797 781 785 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN</italic>
Correlation of NB stage with MYCN:DeltaMYCN-ratio showed that the MYCN:DeltaMYCN-ratio remains constant and does not change with either MYCN-amplification (Figure 3C; two-tailed p-value = 0.09, calculated with the Students' T-test) or NB stage (Figure 3F; two-tailed p-value = 0.12, calculated with the Spearman rank correlation). However, there is a significant correlation between the MYCN:MYCNOS-ratio and both MYCN-amplification (Figure 3C; two-tailed p-value = 0.025) and NB-stage (Figure 3E; two-tailed p-value = 0.007). The MYCNOS:DeltaMYCN-ratio did not significantly change with either MYCN-amplification or NB-stage (two-tailed p-values = 0.58 and 0.24, respectively; data not shown). These data show that in more advanced NB tumours, mRNA expression of MYCNOS increases relative to MYCN.
###end p 50
###begin title 51
DeltaMYCN and MYCNOS expression relative to level of MYCN-amplification
###end title 51
###begin p 52
###xml 26 31 26 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 195 199 195 199 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN</italic>
###xml 213 215 213 215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A</xref>
###xml 223 224 223 224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 338 342 338 342 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CFTR</italic>
###xml 344 349 344 349 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TBX22</italic>
###xml 355 362 355 362 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SLC16A2</italic>
###xml 498 502 498 502 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN</italic>
###xml 575 580 575 580 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 629 634 629 634 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 694 699 694 699 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 795 796 795 796 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 797 799 797 799 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 840 844 840 844 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN</italic>
###xml 920 925 920 925 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 952 953 952 953 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 1031 1035 1031 1035 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN</italic>
###xml 1051 1053 1051 1053 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
To more exactly determine MYCN copy number in the tumours that were studied, we performed a genomic quantitative PCR (gQPCR) using genomic primers recognizing five different locations within the MYCN-gene (Figure 1A; Table 1). Amplification of these DNA fragments was calculated relative to three reference genes elsewhere on the genome, CFTR, TBX22, and SLC16A2. Among these three reference genes, there were no copy number differences noted in any of the NB samples. All 10 samples with a normal MYCN-copy number based on Southern blotting and/or FISH, carried two to four MYCN copies as determined by gQPCR. The presence of a MYCN duplication in NB cells that lack an overt amplification of MYCN is more often found, although the implications for the progression of the NB are still unclear [5,27]. All 6 samples with multiple copies of MYCN, as determined by Southern blotting and/or FISH, had in between 20 and 139 MYCN gene amplifications (Table 2), which is within the normal range of gene copy numbers observed in NBs with MYCN-amplification [28].
###end p 52
###begin p 53
###xml 17 22 17 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 71 76 71 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN-</italic>
###xml 124 126 124 126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 147 157 147 153 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#916;MYCN </italic>
###xml 161 168 157 164 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCNOS </italic>
###xml 213 218 209 214 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 238 240 234 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3B</xref>
###xml 262 264 258 260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3D</xref>
###xml 304 316 300 312 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN:MYCNOS </italic>
###xml 355 360 351 356 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 453 454 449 450 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 520 535 516 527 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN:&#916;MYCN </italic>
###xml 569 574 561 566 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 595 597 587 589 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3D</xref>
###xml 637 638 629 630 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
We observed that MYCN mRNA-expression does not linearly correlate with MYCN-amplification, consistent with earlier reports [26]. In addition, also DeltaMYCN and MYCNOS do not correlate linearly with the number of MYCN gene copies (Figure 3B). As shown in figure 3D, the relative mRNA expression ratio of MYCN:MYCNOS decreases with an increasing number of MYCN gene copies although this is not significant (non-interrupted line, slope = -0.4; two-tailed p-value = 0.18, calculated with the Pearson correlation test). The MYCN:DeltaMYCN ratio does not change with higher MYCN copy numbers (Figure 3D; dotted line, slope = -0.1; two-tailed p-value = 0.88).
###end p 53
###begin title 54
###xml 18 25 18 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCNOS </italic>
Overexpression of MYCNOS in the NB cell line IMR-32
###end title 54
###begin p 55
###xml 16 22 16 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCNOS</italic>
###xml 45 50 45 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 109 113 109 113 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN</italic>
###xml 125 132 125 132 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCNOS </italic>
###xml 157 162 157 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 250 255 250 255 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 280 282 280 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 346 350 346 350 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GFP </italic>
###xml 390 397 390 397 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCNOS </italic>
###xml 483 487 483 487 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN</italic>
###xml 489 496 489 496 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCNOS </italic>
###xml 500 509 500 505 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#916;MYCN</italic>
###xml 669 671 665 667 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4A</xref>
###xml 715 722 711 718 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCNOS </italic>
###xml 745 751 741 747 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCNOS</italic>
###xml 829 831 825 827 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4B</xref>
###xml 859 864 855 860 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 868 878 864 870 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#916;MYCN </italic>
###xml 952 957 944 949 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4B, C</xref>
###xml 1144 1151 1136 1143 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCNOS </italic>
###xml 1165 1170 1157 1162 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 1209 1224 1201 1212 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN:&#916;MYCN </italic>
###xml 1244 1251 1232 1239 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCNOS </italic>
###xml 1277 1284 1265 1272 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCNOS </italic>
The pre-mRNA of MYCNOS, which represents the MYCN antisense transcript, shows overlap with the first exon of MYCN. Therefore MYCNOS may potentially modulate MYCN mRNA expression levels at the mRNA level via RNA-interference or RNA-editing, or direct MYCN splicing by RNA masking [11]. To test this premise, we transfected IMR-32 NB cells with C1-GFP and either the pcDNA3-vector containing MYCNOS or an empty vector. IMR-32 cells have relatively high endogenous expression levels of MYCN, MYCNOS and DeltaMYCN, which enables quantification of all three mRNA levels. Flow cytometric analyses showed that there was a transfection efficiency of 74% after 72 hours (Figure 4A). Although there was a 50-fold increase of MYCNOS gene expression in the MYCNOS-transfected cell line relative to the empty vector control cell line (Figure 4B), expression of endogenous MYCN and DeltaMYCN was not affected either at the mRNA level or at the protein level (Figure 4B, C). We conclude that although increased expression of MYCNOS relative to MYCN is correlated with an advanced disease state, RNA-interference or RNA-editing are not the mechanisms by which MYCNOS downregulates MYCN expression. In addition, the unchanged MYCN:DeltaMYCN ratio in cells with MYCNOS overexpression shows that MYCNOS does not affect splicing by RNA-masking.
###end p 55
###begin p 56
###xml 18 25 18 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCNOS </italic>
###xml 0 51 0 51 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Overexpression of <italic>MYCNOS </italic>in the NB cell line IMR-32</bold>
###xml 217 224 217 224 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCNOS </italic>
###xml 250 257 250 257 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCNOS </italic>
###xml 351 356 351 356 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 456 463 456 463 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCNOS </italic>
###xml 652 659 652 659 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCNOS </italic>
Overexpression of MYCNOS in the NB cell line IMR-32. (A) Transfection-efficiency was measured by GFP expression as analysed by flow cytometry, 74% of the NB cells expressed GFP 72 hours after transfection. (B) In the MYCNOS transfected IMR-32 cells, MYCNOS was 50x upregulated compared to not transfected and mock-transfected IMR-32 cells. Endogenous MYCN expression was not significantly affected. (C) Western blot showing that MYCN protein expression in MYCNOS transfected IMR-32 cells was unaffected. Lane 1 is loaded with lysate from untransfected cells, lane 2 with lysate from cells transfected with the empty vector, and lane 3 with lysate from MYCNOS transfected cells.
###end p 56
###begin title 57
Discussion
###end title 57
###begin p 58
###xml 58 62 58 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN</italic>
###xml 64 74 64 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#916;MYCN </italic>
###xml 78 85 74 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCNOS </italic>
###xml 199 203 195 199 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN</italic>
###xml 223 235 219 231 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN:MYCNOS </italic>
###xml 316 331 312 323 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN:&#916;MYCN </italic>
###xml 391 396 383 388 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 400 410 392 398 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#916;MYCN </italic>
###xml 455 462 443 450 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCNOS </italic>
###xml 501 506 489 494 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 634 636 622 624 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 637 639 625 627 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 830 837 818 825 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCNOS </italic>
###xml 858 863 846 851 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 778 786 <span type="species:ncbi:9606">patients</span>
###xml 877 885 <span type="species:ncbi:9606">patients</span>
In this report, we have analysed the expression levels of MYCN, DeltaMYCN and MYCNOS in NBs. We find that these three mRNA transcripts are expressed in NBs of all stages, but more highly in NBs with MYCN-amplification. The MYCN:MYCNOS expression level ratio is significantly decreased in high grade NBs, whereas the MYCN:DeltaMYCN remains constant in NBs of all stages, which indicates that MYCN and DeltaMYCN are co-regulated. These results suggest that MYCNOS might be involved in the regulation of MYCN expression levels as has been shown for numerous other antisense transcripts regulating expression of their sense counterparts [11,12]. However, it is important to note that the number of NB samples we investigated is relatively small. Future studies in larger cohorts of patients are needed to further establish a role for MYCNOS in the regulation of MYCN expression in patients with low-, intermediate- and high-risk NB.
###end p 58
###begin p 59
###xml 193 195 193 195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 196 198 196 198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 217 229 217 229 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN-MYCNOS </italic>
###xml 287 292 287 292 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 355 365 355 361 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#916;MYCN </italic>
###xml 385 390 381 386 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 393 395 389 391 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 477 482 473 478 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 501 508 497 504 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCNOS </italic>
###xml 555 562 551 558 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCNOS </italic>
###xml 632 639 628 635 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCNOS </italic>
###xml 674 678 670 674 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN</italic>
###xml 679 689 675 681 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#916;MYCN </italic>
###xml 751 756 743 744 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#916;</italic>
###xml 757 762 745 750 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 810 816 798 804 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCNOS</italic>
###xml 990 997 978 985 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCNOS </italic>
Natural antisense RNA can inhibit gene expression at the DNA level by transcriptional interference or at the mRNA level by RNA-interference or RNA-editing, or regulate splicing by RNA-masking [11,12]. In RNA-masking, MYCN-MYCNOS duplex formation modulates RNA processing by preserving a MYCN population that retains intron 1, hence resulting in decreased DeltaMYCN expression. Krystal et al. [29] showed that RNA-masking can occur, but they found that only approximately 5% of MYCN RNA interacts with MYCNOS RNA. Our results show that it is unlikely that MYCNOS expression has an effect on splicing, since 50-fold overexpression of MYCNOS in IMR-32 cells did not change the MYCN/DeltaMYCN expression ratio at the mRNA level. Therefore, inhibition of (Delta)MYCN expression seems to be the most likely role for MYCNOS. There are three mechanisms by which this may be accomplished: transcriptional interference, RNA interference and RNA-editing. Since our results show that overexpression of MYCNOS pre-mRNA in NB cell line IMR-32 does not suppress MYCN expression, RNA-interference and RNA-editing do not seem to be the primary inhibitory mechanisms, leaving the possibility that regulation occurs at the DNA level by steric hindrance of the voluminous RNA-polymerase complexes on opposite DNA strands.
###end p 59
###begin p 60
###xml 44 51 44 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCNOS </italic>
###xml 114 121 114 121 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCNOS </italic>
###xml 162 167 162 167 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 297 302 297 302 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN-</italic>
###xml 368 380 368 380 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN:MYCNOS </italic>
###xml 430 437 430 437 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCNOS </italic>
###xml 501 506 501 506 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 550 551 550 551 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 552 553 552 553 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 255 263 <span type="species:ncbi:9606">patients</span>
###xml 268 276 <span type="species:ncbi:9606">patients</span>
###xml 540 548 <span type="species:ncbi:9606">patients</span>
It is not clear how increased expression of MYCNOS contributes to the development of NB. Although the increase of MYCNOS expression levels is higher than that of MYCN in NB with amplification, this difference does not appear to influence the prognosis of patients. In patients with NB but without MYCN-amplification, it would be interesting to investigate whether the MYCN:MYCNOS ratio is a good prognostic marker. Differences in MYCNOS expression levels might explain some of the controversies about MYCN expression and prognosis of these patients [1-3].
###end p 60
###begin p 61
###xml 8 13 8 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 17 23 17 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCNOS</italic>
###xml 25 34 25 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#916;MYCN</italic>
###xml 91 93 87 89 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 131 136 127 132 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 264 266 260 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 384 394 380 386 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#916;MYCN </italic>
###xml 459 469 451 457 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#916;MYCN </italic>
###xml 516 521 504 509 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 925 927 905 907 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 1071 1075 1047 1051 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN</italic>
Besides MYCN and MYCNOS, DeltaMYCN, which was previously identified as a fetal transcript [18], is also expressed in NBs. No other MYCN isoforms were detected. This suggests that the alternative splice variant that previously has been described by Stanton et al. [30] and consists of an alternatively spliced exon 1, has little relevance in the progression of NBs. In one tumour, the DeltaMYCN transcript could not be identified, but this is probably because DeltaMYCN is low expressed in general and in this tumour MYCN was not amplified. The DeltaMYCN protein contains a nuclear localization signal, a basic helix-loop-helix, and a leucine-zipper domain, which may serve to dimerize with MYCN or bind to its DNA binding site. DeltaMYCN lacks the transactivation domain including the highly conserved Myc 1 and 2 boxes, from which it was speculated that it competes with MYCN and therefore inhibits the active MYCN protein [18]. However, in all neuroblastoma samples analyzed, the ratio between MYCN and DeltaMYCN expression remains constant and does not correlate with MYCN-amplification or disease stage, indicating that DeltaMYCN induced inhibition of MYCN at the protein level is not of relevance in NB.
###end p 61
###begin title 62
Conclusion
###end title 62
###begin p 63
###xml 77 84 77 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCNOS </italic>
###xml 163 168 163 168 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
###xml 244 256 244 256 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN:MYCNOS </italic>
###xml 302 307 302 307 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN-</italic>
###xml 388 395 388 395 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCNOS </italic>
###xml 277 285 <span type="species:ncbi:9606">patients</span>
###xml 432 440 <span type="species:ncbi:9606">patients</span>
In conclusion, our results suggest that the expression of the antisense gene MYCNOS might be relevant to the progression of NB, potentially by directly inhibiting MYCN transcription by transcriptional interference at the DNA level. Analysis of MYCN:MYCNOS expression ratios in patients with NB without MYCN-amplification and clinical follow-up are necessary to establish the relevance of MYCNOS expression to the prognosis of these patients.
###end p 63
###begin title 64
Competing interests
###end title 64
###begin p 65
The authors declare that they have no competing interests.
###end p 65
###begin title 66
Authors' contributions
###end title 66
###begin p 67
JFMJ and APMB designed, performed and analyzed the research and drafted the manuscript. HB and PH conceived of the study. FNL supervised the transfection experiments and helped to draft the manuscript. CAHK performed all pathological characterizations. HB, PMH, GJA and IJMV conducted the study as the principal investigators and contributed to the preparation of the manuscript. All authors read and approved the final manuscript.
###end p 67
###begin title 68
Pre-publication history
###end title 68
###begin p 69
The pre-publication history for this paper can be accessed here:
###end p 69
###begin p 70

###end p 70
###begin title 71
Supplementary Material
###end title 71
###begin title 72
Additional file 1
###end title 72
###begin p 73
###xml 0 19 0 19 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Supplemental figure</bold>
###xml 79 81 79 81 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2a</xref>
Supplemental figure. Ponceau S stainings of the immunoblot shown in (A) figure 2a and (B) 4c
###end p 73
###begin p 74
Click here for file
###end p 74
###begin title 75
Acknowledgements
###end title 75
###begin p 76
The authors would like to thank Dorien Lugtenberg and Jolein Gloerich for technical assistance with the quantitative PCR and the mass spectrometry, respectively. Arjan P.M. de Brouwer was supported by a grant from the Maag-Darm-Lever stichting (grant nr MWO 05-71).
###end p 76
###begin article-title 77
###xml 27 32 27 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
Prognostic significance of MYCN oncogene expression in childhood neuroblastoma
###end article-title 77
###begin article-title 78
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
MYCN expression in neuroblastoma: A mixed message?
###end article-title 78
###begin article-title 79
###xml 33 38 33 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
The MYCN enigma: significance of MYCN expression in neuroblastoma
###end article-title 79
###begin article-title 80
###xml 24 29 24 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
Genes co-amplified with MYCN in neuroblastoma: silent passengers or co-determinants of phenotype?
###end article-title 80
###begin article-title 81
MYCN in neuronal tumours
###end article-title 81
###begin article-title 82
###xml 18 22 18 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN</italic>
###xml 24 28 24 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DDX1</italic>
###xml 34 38 34 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAG </italic>
Quantification of MYCN, DDX1, and NAG gene copy number in neuroblastoma using a real-time quantitative PCR assay
###end article-title 82
###begin article-title 83
###xml 29 34 <span type="species:ncbi:9606">human</span>
Antisense transcripts in the human genome
###end article-title 83
###begin article-title 84
###xml 64 69 <span type="species:ncbi:9606">human</span>
###xml 74 79 <span type="species:ncbi:10090">mouse</span>
Computational discovery of sense-antisense transcription in the human and mouse genomes
###end article-title 84
###begin article-title 85
###xml 18 41 <span type="species:ncbi:7227">Drosophila melanogaster</span>
Annotation of the Drosophila melanogaster euchromatic genome: a systematic review
###end article-title 85
###begin article-title 86
###xml 56 61 <span type="species:ncbi:9606">human</span>
Widespread occurrence of antisense transcription in the human genome
###end article-title 86
###begin article-title 87
In search of antisense
###end article-title 87
###begin article-title 88
Overlapping genes in vertebrate genomes
###end article-title 88
###begin article-title 89
###xml 56 61 56 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N-cym</italic>
###xml 108 113 108 113 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N-myc</italic>
Isolation and characterization of complementary DNA for N-cym, a gene encoded by the DNA strand opposite to N-myc
###end article-title 89
###begin article-title 90
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">aHIF </italic>
###xml 55 60 <span type="species:ncbi:9606">human</span>
aHIF : a natural antisense transcript overexpressed in human renal cancer and during hypoxia
###end article-title 90
###begin article-title 91
###xml 35 41 35 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGF-2 </italic>
###xml 45 49 45 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGF </italic>
Coexpression and regulation of the FGF-2 and FGF antisense genes in leukemic cells
###end article-title 91
###begin article-title 92
###xml 33 65 33 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink">hypoxia-inducible factor 1alpha </italic>
###xml 109 114 <span type="species:ncbi:9606">human</span>
Natural antisense transcripts of hypoxia-inducible factor 1alpha are detected in different normal and tumour human tissues
###end article-title 92
###begin article-title 93
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">aHIF </italic>
###xml 13 24 13 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HIF-1alpha </italic>
###xml 66 71 <span type="species:ncbi:9606">human</span>
aHIF but not HIF-1alpha transcript is a poor prognostic marker in human breast cancer
###end article-title 93
###begin article-title 94
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
MYCN haploinsufficiency is associated with reduced brain size and intestinal atresias in Feingold syndrome
###end article-title 94
###begin article-title 95
Primer3 on the WWW for general users and for biologist programmers
###end article-title 95
###begin article-title 96
###xml 35 39 35 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN</italic>
Genotype-phenotype correlations in MYCN-related Feingold syndrome
###end article-title 96
###begin article-title 97
###xml 80 98 <span type="species:ncbi:10376">Epstein-Barr virus</span>
Comparison of 12 reference genes for normalization of gene expression levels in Epstein-Barr virus-transformed lymphoblastoid cell lines and fibroblasts
###end article-title 97
###begin article-title 98
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method
###end article-title 98
###begin article-title 99
A new mathematical model for relative quantification in real-time RT-PCR
###end article-title 99
###begin article-title 100
Real-time quantitative PCR as an alternative to Southern blot or fluorescence in situ hybridization for detection of gene copy number changes
###end article-title 100
###begin article-title 101
###xml 82 90 <span type="species:ncbi:9606">patients</span>
###xml 146 154 <span type="species:ncbi:9606">Children</span>
International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group
###end article-title 101
###begin article-title 102
###xml 97 102 97 102 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN </italic>
Clinical significance of a highly sensitive analysis for gene dosage and the expression level of MYCN in neuroblastoma
###end article-title 102
###begin article-title 103
###xml 15 21 15 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N-MYC </italic>
###xml 112 117 <span type="species:ncbi:9606">human</span>
Duplication of N-MYC at its resident site 2p24 may be a mechanism of activation alternative to amplification in human neuroblastoma cells
###end article-title 103
###begin article-title 104
###xml 38 44 38 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N-myc </italic>
###xml 27 32 <span type="species:ncbi:9606">human</span>
Enhanced expression of the human gene N-myc consequent to amplification of DNA may contribute to malignant progression of neuroblastoma
###end article-title 104
###begin article-title 105
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N-myc </italic>
N-myc mRNA forms an RNA-RNA duplex with endogenous antisense transcripts
###end article-title 105
###begin article-title 106
Alternative processing of RNA transcribed from NMYC
###end article-title 106
###begin article-title 107
###xml 101 109 <span type="species:ncbi:9606">Children</span>
Favorable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy: a Children's Cancer Group study
###end article-title 107

